Polio – end game quiz

Quiz derived from the IPV Injectable Polio Vaccine Presentation given in August 2013 from Small Group Meeting at Chandigarh

1. Polio – End Game Quiz Dr Gaurav Gupta Source: IAP ADVAC Program

2. All of the following are risks for polio re-emergence after termination of wild virus transmission: a. Laboratories that work with wild polioviruses b. Chronic immune deficient shedders c. Continued use of oral polio vaccines d. Continued use of wild polio viruses to make inactivated polio vaccine e. Bioterrorism f. All of the above

3. All of the following are risks for polio re-emergence after termination of wild virus transmission: a. Laboratories that work with wild polioviruses b. Chronic immune deficient shedders c. Continued use of oral polio vaccines d. Continued use of wild polio viruses to make inactivated polio vaccine e. Bioterrorism f. All of the above

4. Circulating vaccine-derived polioviruses have the same characteristics as wild polioviruses False True 

5. Circulating vaccine-derived polioviruses have the same characteristics as wild polioviruses False True 

6. The most common cause of circulating vaccine derived poliovirus outbreaks in recent years is: Type 1 Type 2 Type 3 Mixed types

7. The most common cause of circulating vaccine derived poliovirus outbreaks in recent years is: Type 1 Type 2 Type 3 Mixed types

8. Oral polio vaccines are characterized by all of the following EXCEPT: Have lower efficacy in tropical countries than in industrialized countries Spread from vaccinees to non- vaccinees , thereby enhancing immunity Cause vaccine-associated paralytic polio (VAPP) in vaccine recipients but not contacts Can lead to viruses with the transmissibility and neurovirulence characteristics of wild viruses

9. Oral polio vaccines are characterized by all of the following EXCEPT: Have lower efficacy in tropical countries than in industrialized countries Spread from vaccinees to non- vaccinees , thereby enhancing immunity Cause vaccine-associated paralytic polio (VAPP) in vaccine recipients but not contacts Can lead to viruses with the transmissibility and neurovirulence characteristics of wild viruses

10. Cases of vaccine-associated paralytic polio are as clinically severe as cases of wild virus polio False True 

11. Cases of vaccine-associated paralytic polio are as clinically severe as cases of wild virus polio False True  

12. All of the following are true about inactivated polio vaccine (IPV) except: IPV is made from wild polio viruses IPV must be given by injection IPV is equivalent to oral polio vaccine (OPV) in inducing immunity in the oral cavity IPV is equivalent to OPV in inducing immunity in the intestine

13. All of the following are true about inactivated polio vaccine (IPV) except: IPV is made from wild polio viruses IPV must be given by injection IPV is equivalent to oral polio vaccine (OPV) in inducing immunity in the oral cavity IPV is equivalent to OPV in inducing immunity in the intestine

14. All of the following are true with regard to VAPP EXCEPT: It can occur in contacts as well as recipients Persons with B cell immune deficiencies have the highest risk The most common type associated with VAPP is type 1 Most cases of VAPP have no identified risk factors

15. All of the following are true with regard to VAPP EXCEPT: It can occur in contacts as well as recipients Persons with B cell immune deficiencies have the highest risk The most common type associated with VAPP is type 1 Most cases of VAPP have no identified risk factors

16. Immune deficient persons can excrete polioviruses for many years and can develop clinical polio years after their initial infection. False True 

17. Immune deficient persons can excrete polioviruses for many years and can develop clinical polio years after their initial infection. False True  

18. All of the following are being considered for the polio endgame EXCEPT: Development of antiviral drugs to treat immune deficient chronic poliovirus shedders Stopping OPV as soon as it is safe to do so Establishing special procedures to contain virus in laboratories Making IPV affordable for developing countries Establishing a stockpile of trivalent Oral Polio Vaccine

19. All of the following are being considered for the polio endgame EXCEPT: Development of antiviral drugs to treat immune deficient chronic poliovirus shedders Stopping OPV as soon as it is safe to do so Establishing special procedures to contain virus in laboratories Making IPV affordable for developing countries Establishing a stockpile of trivalent Oral Polio Vaccine

20. All of the following are ways to make IPV more affordable EXCEPT: Oral delivery Intradermal delivery Decrease number of doses Use seed strains other than the wild virus Add adjuvants to the vaccine

21. All of the following are ways to make IPV more affordable EXCEPT: Oral delivery Intradermal delivery Decrease number of doses Use seed strains other than the wild virus Add adjuvants to the vaccine